The effect of medroxyprogesterone acetate on gonadotropin secretion in girls with precocious puberty

Mp, Warren; Jh, Mathews; Morishima, Akira; R, Vande Wiele

doi:10.1097/00000441-197505000-00010

Cited by 8 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even prior to the development of GnRH agonist medications, progestins, more specifically medroxyprogesterone acetate, had been used in the treatment of precocious puberty to suppress sex hormone production. 84 Progestins, including medroxyprogesterone acetate and norethindrone, reduce the pulsatile release of LH and also directly inhibit sex hormone production at the level of the gonad. 6 Medroxyprogesterone acetate can be given as an intramuscular injection every 3 months (Depo-Provera®) or as a daily oral medication (Provera®), and norethindrone as a daily oral medication (as Micronor® or Aygestin®).…”

Section: Prevention Of the Development Of Unwanted Secondary Sex Charmentioning

confidence: 99%

Advances in the Care of Transgender Children and Adolescents

Shumer

Nokoff

Spack

2016

Advances in Pediatrics

View full text Add to dashboard Cite

Children and adolescents with gender dysphoria are presenting for medical attention at increasing rates. Standards of Care have been developed which outline appropriate mental health support and hormonal interventions for transgender youth. This article defines terminology related to gender identity, reviews the history of medical interventions for transgender persons, outlines what is known about gender identity development, and reviews mental health disparities faced by this patient population. We provide an overview of medical management options for transgender adolescents meeting diagnostic criteria for gender dysphoria including pubertal suppression, cross-sex hormones, longitudinal screening and anticipatory guidance. We describe current challenges in the field and provide information about how care is currently being provided in the US and Canada. We conclude with 5 brief case examples.

show abstract

Section: Prevention Of the Development Of Unwanted Secondary Sex Charmentioning

confidence: 99%

Advances in the Care of Transgender Children and Adolescents

Shumer

Nokoff

Spack

2016

Advances in Pediatrics

View full text Add to dashboard Cite

show abstract

“…It was typically administered either orally at a dose of 10 mg per day or in the form of an intramuscular injection of 100–150 mg every 2 weeks. MPA decreased gonadotropin levels to a variable degree in both boys and girls [51-53]. Girls usually experienced cessation of menses along with regression of both breast development and estrogenization of the vaginal mucosa.…”

Section: Central Precocious Pubertymentioning

confidence: 99%

History of Puberty: Normal and Precocious

Fuqua¹,

Eugster²

2022

Horm Res Paediatr

View full text Add to dashboard Cite

Spanning from bench to bedside, the history of normal and precocious puberty is characterized by a series of remarkable advances that have illuminated reproductive physiology and profoundly impacted clinical care. Early recognition of the hypothalamic and pituitary control of ovarian and testicular function led to the identification of GnRH as the key driver of pubertal onset. Decades later, discovery of the kisspeptin system further refined our understanding of human reproductive neuroendocrinology. Development of long-acting analogs of GnRH revolutionized the treatment of precocious puberty worldwide and ushered in the current era of an ever-expanding therapeutic armamentarium. Identification of monogenic etiologies of precocious puberty has further illustrated the exquisite complexity that comprises neurosecretory modulation of the hypothalamic GnRH neuron and may well lead to exciting novel targeted therapies.

show abstract

“…53,81,82 Before the availability of GnRHa, progestins such as medroxyprogesterone or cyproterone acetate, depending on the geographical location of clinical practice, were the mainstay of therapy for children with CPP. [83][84][85] The use of depot or oral medroxyprogesterone can be considered, especially in settings where GnRH agonist is too costly or not available; however, GnRH agonist should be utilized as first-line therapy when possible due to better efficacy and an improved side effect profile. 3,86 The anti-androgen, cyproterone acetate, available outside of the United States, has been widely used in adult transwoman to suppress endogenous androgens and there is some experience reported in adolescents, although effects on growth velocity were not studied.…”

Section: Alternative S To G Nrha For Pub Ertal Suppre Ss Ionmentioning

confidence: 99%

“…Administration of GnRHa for TGD with gender dysphoria may vary based on local availability, comfort level of the medical provider, cost and/or insurance coverage 53,81,82 . Before the availability of GnRHa, progestins such as medroxyprogesterone or cyproterone acetate, depending on the geographical location of clinical practice, were the mainstay of therapy for children with CPP 83‐85 . The use of depot or oral medroxyprogesterone can be considered, especially in settings where GnRH agonist is too costly or not available; however, GnRH agonist should be utilized as first‐line therapy when possible due to better efficacy and an improved side effect profile 3,86 .…”

Section: Alternatives To Gnrha For Pubertal Suppressionmentioning

confidence: 99%

Growth, growth potential, and influences on adult height in the transgender and gender‐diverse population

Roberts

Carswell

2021

Andrology

View full text Add to dashboard Cite

The sexually dimorphic trait of height is one aspect of the experience of transgender and gender-diverse (TGD) individuals that may influence their gender dysphoria and satisfaction with their transition. In this article, we have reviewed the current knowledge of the factors that contribute to one's final adult height and how it might be affected in TGD youth who have not experienced their gonadal puberty in the setting of receiving gonadotropin-releasing hormone analog (GnRHa) and gender-affirming hormonal treatment. Additional research is needed to characterize the influence of growth and final adult height on the lived experience of TGD youth and adults and how to best assess their growth, predict their final adult height, and how medical transition can be potentially modified to help them meet their goals.

show abstract

The effect of medroxyprogesterone acetate on gonadotropin secretion in girls with precocious puberty

Cited by 8 publications

References 0 publications

Advances in the Care of Transgender Children and Adolescents

Advances in the Care of Transgender Children and Adolescents

History of Puberty: Normal and Precocious

Growth, growth potential, and influences on adult height in the transgender and gender‐diverse population

Contact Info

Product

Resources

About